Pulse Biosciences (NASDAQ:PLSE – Get Rating) announced its earnings results on Thursday. The company reported ($0.52) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.51) by ($0.01), Fidelity Earnings reports. During the same period in the prior year, the firm earned ($0.54) EPS.
Shares of NASDAQ:PLSE opened at $4.86 on Friday. The firm’s 50 day moving average price is $6.74 and its 200 day moving average price is $14.74. The stock has a market cap of $144.01 million, a price-to-earnings ratio of -2.10 and a beta of 1.61. Pulse Biosciences has a fifty-two week low of $4.14 and a fifty-two week high of $29.16.
A number of large investors have recently modified their holdings of the stock. Royal Bank of Canada raised its holdings in Pulse Biosciences by 43.2% in the third quarter. Royal Bank of Canada now owns 2,324 shares of the company’s stock valued at $50,000 after acquiring an additional 701 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in Pulse Biosciences by 3.8% during the third quarter. Bank of New York Mellon Corp now owns 39,747 shares of the company’s stock worth $858,000 after purchasing an additional 1,438 shares in the last quarter. Charles Schwab Investment Management Inc. raised its holdings in Pulse Biosciences by 4.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 36,094 shares of the company’s stock worth $535,000 after purchasing an additional 1,540 shares in the last quarter. Citigroup Inc. raised its holdings in Pulse Biosciences by 116.1% during the fourth quarter. Citigroup Inc. now owns 3,667 shares of the company’s stock worth $54,000 after purchasing an additional 1,970 shares in the last quarter. Finally, BNP Paribas Arbitrage SA raised its holdings in Pulse Biosciences by 194.2% during the third quarter. BNP Paribas Arbitrage SA now owns 3,101 shares of the company’s stock worth $67,000 after purchasing an additional 2,047 shares in the last quarter. 13.70% of the stock is currently owned by hedge funds and other institutional investors.
Several research analysts have weighed in on the stock. Zacks Investment Research raised shares of Pulse Biosciences from a “sell” rating to a “hold” rating in a research note on Wednesday, March 9th. StockNews.com began coverage on shares of Pulse Biosciences in a research report on Thursday. They set a “sell” rating on the stock. Stephens reduced their price target on shares of Pulse Biosciences from $14.00 to $12.00 and set an “overweight” rating on the stock in a research report on Friday. Finally, HC Wainwright reduced their price target on shares of Pulse Biosciences from $20.00 to $8.50 and set a “buy” rating on the stock in a research report on Friday.
Pulse Biosciences Company Profile
Pulse Biosciences, Inc operates as an immuno-oncology company developing a proprietary oncolytic electroceutical therapy based on its Nano Pulse Stimulation (NPS) technology. It manufactures surgical and medical instruments uses a novel and proprietary platform technology called Nano-Pulse Electro-Signaling.